|
Patent landscape, scope, and claims: |
Understanding the Scope and Claims of United States Patent 10,849,891
Introduction
The United States Patent 10,849,891, assigned to Acadia Pharmaceuticals Inc., is a significant patent in the pharmaceutical sector, particularly related to formulations of pimavanserin. To grasp the full implications of this patent, it is crucial to delve into its scope, claims, and the broader patent landscape.
Patent Overview
The patent in question, 10,849,891, pertains to specific formulations of pimavanserin, a drug used primarily for the treatment of psychosis associated with Parkinson’s disease. Here is a brief overview of the patent:
- Title: Formulations of Pimavanserin
- Assignees: Acadia Pharmaceuticals Inc.
- Priority Date: August 30, 2017[5].
Scope of the Patent
The scope of a patent is defined by its claims, which outline the specific inventions or innovations that are protected.
Claims Analysis
The claims of the 10,849,891 patent are detailed and specific, focusing on various aspects of pimavanserin formulations. Here are some key points:
- Composition Claims: These claims describe the specific formulations of pimavanserin, including the active ingredient, excipients, and the method of preparation.
- Dosage Forms: The patent covers various dosage forms such as tablets, capsules, and other oral formulations.
- Pharmaceutical Properties: Claims may also include specifications related to the pharmaceutical properties of the formulations, such as stability, bioavailability, and shelf life[5].
Claim-by-Claim Analysis
A detailed claim-by-claim analysis is essential to understand the patent's scope and potential infringement issues.
- Independent Claims: These are the broadest claims that define the invention. For example, an independent claim might describe a specific formulation of pimavanserin.
- Dependent Claims: These claims are narrower and depend on the independent claims. They might specify particular aspects of the formulation, such as the ratio of active ingredient to excipients[4].
Patent Landscape
The patent landscape surrounding 10,849,891 includes other related patents and ongoing legal proceedings.
Related Patents
Other patents related to pimavanserin formulations include:
- 10,646,480: This patent, also assigned to Acadia Pharmaceuticals Inc., covers similar formulations and is often cited in conjunction with the 10,849,891 patent.
- 10,517,860: This patent is part of the same family and deals with different aspects of pimavanserin formulations[4].
Litigation and Legal Proceedings
The 10,849,891 patent has been involved in several legal disputes, particularly with generic drug manufacturers.
- Infringement Litigation: Companies like Zydus have been involved in litigation with Acadia Pharmaceuticals Inc. over the alleged infringement of this and related patents. For instance, Zydus’s ANDA (Abbreviated New Drug Application) for a generic version of pimavanserin has been the subject of court proceedings[4].
- Non-infringement Stipulations: In some cases, stipulations have been made where the generic manufacturer agrees that their product does not infringe on certain claims of the patent, based on specific constructions of the claim language[4].
Expiration and Patent Life
Understanding the expiration dates of patents is crucial for both the patent holder and potential infringers.
- Expiration Date: The patent 10,849,891, along with related patents like 10,646,480 and 10,517,860, is set to expire on August 27, 2038, assuming no extensions or adjustments[4].
Impact on the Pharmaceutical Industry
This patent significantly impacts the pharmaceutical industry, particularly in the development and marketing of generic versions of pimavanserin.
- Generic Competition: The expiration of this patent will open the market to generic competition, potentially reducing the cost of the drug and increasing accessibility.
- Research and Development: The protection afforded by this patent allows Acadia Pharmaceuticals Inc. to recoup their investment in research and development, encouraging further innovation in the field[2].
Key Takeaways
- Specific Formulations: The 10,849,891 patent protects specific formulations of pimavanserin, including composition, dosage forms, and pharmaceutical properties.
- Litigation: The patent has been involved in significant litigation with generic drug manufacturers.
- Expiration: The patent is set to expire on August 27, 2038.
- Industry Impact: The patent affects the development and marketing of generic versions of pimavanserin, influencing the pharmaceutical industry’s landscape.
FAQs
-
What is the primary subject of the United States Patent 10,849,891?
- The primary subject is specific formulations of pimavanserin, a drug used for treating psychosis associated with Parkinson’s disease.
-
Who is the assignee of the 10,849,891 patent?
- The assignee is Acadia Pharmaceuticals Inc.
-
What is the significance of the patent's claims?
- The claims define the specific inventions or innovations protected by the patent, including composition, dosage forms, and pharmaceutical properties.
-
What are some related patents to 10,849,891?
- Related patents include 10,646,480 and 10,517,860, which also pertain to pimavanserin formulations.
-
When is the 10,849,891 patent set to expire?
- The patent is set to expire on August 27, 2038.
Sources
- USPTO - Search for patents
- FDA - Pimavanserin Capsules
- USPTO - Patent Claims Research Dataset
- Unified Patents - IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT
- Unified Patents - US-20190047955-A1
More… ↓
⤷ Subscribe
|
